Freichel T, Laaf D, Hoffmann M, Konietzny P, Heine V, Wawrzinek R
RSC Adv. 2022; 9(41):23484-23497.
PMID: 35530592
PMC: 9069326.
DOI: 10.1039/c9ra05497a.
Sethi A, Sanam S, Munagalasetty S, Jayanthi S, Alvala M
RSC Adv. 2022; 10(50):29873-29884.
PMID: 35518264
PMC: 9056307.
DOI: 10.1039/d0ra04795c.
Bernhard S, Goodman C, Norton E, Alme D, Lawrence C, Cloninger M
ACS Omega. 2020; 5(45):29017-29024.
PMID: 33225133
PMC: 7675582.
DOI: 10.1021/acsomega.0c03416.
Dahlqvist A, Mandal S, Peterson K, Hakansson M, Logan D, Zetterberg F
Molecules. 2019; 24(24).
PMID: 31842451
PMC: 6943516.
DOI: 10.3390/molecules24244554.
Seyrek K, Richter M, Lavrik I
Cell Death Differ. 2019; 26(6):981-993.
PMID: 30903104
PMC: 6748114.
DOI: 10.1038/s41418-019-0317-6.
Chemoenzymatic Synthesis of Galectin Binding Glycopolymers.
Ennist J, Termuehlen H, Bernhard S, Fricke M, Cloninger M
Bioconjug Chem. 2018; 29(12):4030-4039.
PMID: 30372040
PMC: 9389845.
DOI: 10.1021/acs.bioconjchem.8b00599.
Galectins as Molecular Targets for Therapeutic Intervention.
Dings R, Miller M, Griffin R, Mayo K
Int J Mol Sci. 2018; 19(3).
PMID: 29562695
PMC: 5877766.
DOI: 10.3390/ijms19030905.
Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.
Koonce N, Griffin R, Dings R
Int J Mol Sci. 2017; 18(12).
PMID: 29232825
PMC: 5751273.
DOI: 10.3390/ijms18122671.
Stereocontrolled 1--glycosylation and comparative binding studies of photoprobe-thiosaccharide conjugates with their -linked analogs.
Deng L, Wang X, Uppalapati S, Norberg O, Dong H, Joliton A
Pure Appl Chem. 2015; 85(9):1789-1801.
PMID: 26180266
PMC: 4500165.
DOI: 10.1351/PAC-CON-12-08-13.
Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.
Dings R, Kumar N, Miller M, Loren M, Rangwala H, Hoye T
J Pharmacol Exp Ther. 2012; 344(3):589-99.
PMID: 23232447
PMC: 3583509.
DOI: 10.1124/jpet.112.199646.
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
Dings R, Miller M, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M
J Med Chem. 2012; 55(11):5121-9.
PMID: 22575017
PMC: 4242090.
DOI: 10.1021/jm300014q.
Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.
Glinskii O, Sud S, Mossine V, Mawhinney T, Anthony D, Glinsky G
Neoplasia. 2012; 14(1):65-73.
PMID: 22355275
PMC: 3281943.
DOI: 10.1593/neo.111544.
Galectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infection.
St-Pierre C, Ouellet M, Giguere D, Ohtake R, Roy R, Sato S
Antimicrob Agents Chemother. 2011; 56(1):154-62.
PMID: 22064534
PMC: 3256073.
DOI: 10.1128/AAC.05595-11.
Structure determination of a Galectin-3-carbohydrate complex using paramagnetism-based NMR constraints.
Zhuang T, Lee H, Imperiali B, Prestegard J
Protein Sci. 2008; 17(7):1220-31.
PMID: 18413860
PMC: 2442008.
DOI: 10.1110/ps.034561.108.